Index of /upload/prescriptii_medicamente/formulare

[ICO]NameLast modifiedSizeDescription
[PARENTDIR]Parent Directory  -  
[ ]vemurafenib.pdf2022-11-14 04:17 243K 
[ ]vandetanib-medular-tiroidian.pdf2022-11-14 04:17 232K 
[ ]tumori-neuroendocrine.pdf2022-11-14 04:17 539K 
[ ]trastuzumab-san-metastatic.pdf2023-02-10 09:36 189K 
[ ]trastuzumab-gastric-metastatic.pdf2023-02-10 09:36 229K 
[ ]trastuzumab-emtansine.pdf2022-11-14 04:17 676K 
[ ]trabectedin-sarcom.pdf2022-11-14 04:17 224K 
[ ]trabectedin-ovar.pdf2022-11-14 04:17 222K 
[ ]tivozanib-renal.pdf2022-11-14 04:17 454K 
[ ]sunitinib-renal.pdf2022-11-14 04:17 128K 
[ ]sunitinib-neuroendocrine.pdf2022-11-14 04:17 589K 
[ ]sunitinib-gist.pdf2022-11-14 04:17 122K 
[ ]sorafenib-tiroida.pdf2022-11-14 04:17 108K 
[ ]sorafenib-renal.pdf2022-11-14 04:17 116K 
[ ]sorafenib-hepatocelular.pdf2022-11-14 04:17 113K 
[ ]ribociclib-mamar.pdf2022-11-14 04:17 232K 
[ ]regorafenib-hepatocelular.pdf2022-11-14 04:17 336K 
[ ]ramucirumab-nsclc.pdf2022-11-14 04:17 441K 
[ ]ramucirumab-gastric.pdf2022-11-14 04:17 481K 
[ ]pertuzumab-trastuzumab-mamar.pdf2022-11-14 04:17 452K 
[ ]pemetrexed-nsclc.pdf2022-11-14 04:17 126K 
[ ]pemetrexed-mezoteliom.pdf2022-11-14 04:17 177K 
[ ]pembrolizumab-nsclc-pemetrexed.pdf2022-11-14 04:17 205K 
[ ]pembrolizumab-nsclc-mono.pdf2022-11-14 04:17 199K 
[ ]pembrolizumab-nsclc-carbo-txl.pdf2022-11-14 04:17 227K 
[ ]pembrolizumab-melanom.pdf2022-11-14 04:17 256K 
[ ]pazopanib-sarcom.pdf2022-11-14 04:17 350K 
[ ]pazopanib-renal.pdf2022-11-14 04:17 287K 
[ ]panitumumab-colorectal.pdf2022-11-14 04:17 114K 
[ ]palbociclib-mamar.pdf2022-11-14 04:17 65K 
[ ]osimertinib-nsclc.pdf2022-11-14 04:17 457K 
[ ]onyvide-pancreas.pdf2022-11-14 04:17 556K 
[ ]olaratumab-sarcom.pdf2022-11-14 04:17 481K 
[ ]olaparib-prostata.pdf2022-11-14 04:17 93K 
[ ]olaparib-over-combi.pdf2022-11-14 04:17 428K 
[ ]olaparib-ovar-mono.pdf2022-11-14 04:17 446K 
[ ]nivolumab-renal.pdf2022-11-14 04:17 244K 
[ ]nivolumab-nsclc.pdf2022-11-14 04:17 245K 
[ ]nivolumab-melanom.pdf2022-11-14 04:17 308K 
[ ]nivolumab-gastric.pdf2022-11-14 04:17 230K 
[ ]nivolumab-cap-si-gat.pdf2022-11-14 04:17 268K 
[ ]nivo-ipi-renal.pdf2022-11-14 04:17 621K 
[ ]lorlatinib-nsclc.pdf2022-11-14 04:17 337K 
[ ]lonsurf.pdf2022-11-14 04:17 203K 
[ ]lapatinib-meta.pdf2022-11-14 04:17 190K 
[ ]lapatinib-linia-1.pdf2022-11-14 04:17 110K 
[ ]ipilimumab-melanom.pdf2022-11-14 04:17 565K 
[ ]imatinib-gist.pdf2022-11-14 04:17 180K 
[ ]imatinib-deramatofibrosarcoma-protuberans.pdf2022-11-14 04:17 169K 
[ ]gefitinib.pdf2022-11-14 04:17 209K 
[ ]everolimus-tumori-neuroendocrine.pdf2022-11-14 04:17 229K 
[ ]everolimus-renal.pdf2022-11-14 04:17 227K 
[ ]erlotinib-pulmonar.pdf2022-11-14 04:17 226K 
[ ]erlotinib-pancreas.pdf2022-11-14 04:17 217K 
[ ]enzalutamid-prechimio.pdf2022-11-14 04:17 277K 
[ ]enzalutamid-postchimio.pdf2022-11-14 04:17 269K 
[ ]durvalumab-sclc.pdf2022-11-14 04:17 447K 
[ ]durvalumab-nsclc.pdf2022-11-14 04:17 620K 
[ ]dabrafenib-trametinib.pdf2022-11-14 04:17 246K 
[ ]crizotinib.pdf2022-11-14 04:17 235K 
[ ]cetuximab-colorectal.pdf2022-11-14 04:17 558K 
[ ]cetuximab-cap-si-gat-metastatic.pdf2022-11-14 04:17 621K 
[ ]ceritinib.pdf2022-11-14 04:17 232K 
[ ]cemiplimab-scc-piele.pdf2022-11-14 04:17 438K 
[ ]cabozantinib-renal.pdf2022-11-14 04:17 241K 
[ ]cabozantinib-hepatocelular.pdf2022-11-14 04:17 444K 
[ ]cabazitaxel.pdf2022-11-14 04:17 102K 
[ ]bevacizumab-renal.pdf2022-11-14 04:17 114K 
[ ]bevacizumab-ovar.pdf2022-11-14 04:17 186K 
[ ]bevacizumab-nsclc-nscc.pdf2022-11-14 04:17 252K 
[ ]bevacizumab-mamar.pdf2022-11-14 04:17 246K 
[ ]bevacizumab-colorectal.pdf2022-11-14 04:17 248K 
[ ]bevacizumab-col-uterin.pdf2022-11-14 04:17 217K 
[ ]avelumab-urotelial.pdf2022-11-14 04:17 273K 
[ ]avelumab-renal.pdf2022-11-14 04:17 449K 
[ ]avelumab-merkel.pdf2022-11-14 04:17 425K 
[ ]atezolizumab-urotelial.pdf2022-11-14 04:17 436K 
[ ]atezolizumab-tnbc.pdf2022-11-14 04:17 447K 
[ ]atezolizumab-sclc.pdf2022-11-14 04:17 427K 
[ ]atezolizumab-nsclc-mono.pdf2022-11-14 04:17 451K 
[ ]atezolizumab-nsclc-combi.pdf2022-11-14 04:17 433K 
[ ]atezolizumab-hepatocelular.pdf2022-11-14 04:17 246K 
[ ]alectinib.pdf2022-11-14 04:17 240K 
[ ]aflibercept.pdf2022-11-14 04:17 176K 
[ ]abirateron-prechimio.pdf2022-11-14 04:17 674K 
[ ]abirateron-postchimio.pdf2022-11-14 04:17 640K 
[ ]abirateron-meta-hormonosensibil-risc-crescut.pdf2022-11-14 04:17 202K 
[ ]abemaciclib-mamar.pdf2022-11-14 04:17 598K 
Apache/2.4.10 (Debian) Server at oncodeva.net Port 443